Federal News
Senators Urge FDA to Schedule Kratom
March 19, 2026
Senators including Pete Ricketts and Richard Blumenthal have formally requested the Food and Drug Administration (FDA) to classify the entire kratom leaf and its derivative 7-hydroxymitragynine (7-OH) as controlled substances under the Controlled Substances Act. This action aims to address growing addiction and safety concerns, particularly among youth, due to the widespread availability of kratom products in various forms. The letter emphasizes the need for comprehensive federal regulation beyond the current focus on only 7-OH.
- Why this matters: Procurement professionals in federal health and regulatory agencies should anticipate potential new regulatory requirements impacting kratom-related products and suppliers.
- Agencies involved in drug enforcement and public health may require updated contracts or services to support expanded scheduling and enforcement activities.
- Contractors specializing in regulatory compliance, testing, and substance control could see increased demand for services aligned with new FDA mandates.
- Organizations supplying kratom or related products should prepare for stricter federal oversight that may affect procurement eligibility and compliance obligations.
Young people across the country have reported growing addicted to kratom supplements, consuming up to a dozen products a day and going through severe withdrawal symptoms after ceasing use.
— U.S. Senator Pete Ricketts
Agencies
Food and Drug Administration, United States Senate, District of Columbia
Locations
Sources
- Rickettsβ Letter Calls on FDA to Address Kratom Scheduling Loophole - Senator Pete Ricketts · Ricketts Senate · Mar 19